Text Size

Stratus Versus Cirrus OCT in AMD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier:
NCT00568191
First received: December 4, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
  Purpose

The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected


Condition
Age-Related Macular Degeneration
Choroidal Neovascularization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Primary Outcome Measures:
  • Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: October 2007
Estimated Study Completion Date: December 2007
Groups/Cohorts
1
retinal thickness program Stratus OCT software 4.0
2
retinal cube 200x200 program of Cirrus OCT

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients aged > 55 years of either sex presenting with age-related macular degeneration

Criteria

Inclusion Criteria:

  • Age>55 years
  • Age-related macular degeneration

Exclusion Criteria:

  • Not consented patients
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568191

Contacts
Contact: Ilse Krebs, MD +43171165 ext 94607 Ilse.Krebs@wienkav.at

Locations
Austria
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery Recruiting
Vienna, Austria, A1030
Contact: Ilse Krebs, MD     +43171165 ext 4607     Ilse.Krebs@wienkav.at    
Principal Investigator: Ilse Krebs, MD            
Sponsors and Collaborators
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Investigators
Principal Investigator: Ilse Krebs Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery
  More Information

No publications provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Prof Susanne Binder, The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier: NCT00568191     History of Changes
Other Study ID Numbers: EK 06-007-VK1
Study First Received: December 4, 2007
Last Updated: December 4, 2007
Health Authority: Austria: Ethikkommission

Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:
Age-related macular degeneration
choroidal neovascularization
Stratus OCT
Cirrus OCT

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
 Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases

ClinicalTrials.gov processed this record on May 16, 2013